Triojection® from SpinaFX Granted Breakthrough Device Designation by U.S. FDA for Minimally Invasive Lumbar Disc Treatment
The Breakthrough Devices Program is designed to expedite the development and review of medical devices that demonstrate clear advantages over existing technologies for serious or life-threatening conditions. This designation grants SpinaFX prioritized access to the FDA, fostering a collaborative approach to regulatory processes and accelerating the path toward commercialization and clinical availability.
A Technological Leap in Spine Care
Triojection is a minimally invasive, image-guided procedure that leverages a proprietary oxygen-ozone delivery system to reduce pressure within the disc and alleviate nerve compression. Unlike more invasive surgical approaches or prolonged conservative treatments that may fail to provide relief, Triojection offers a targeted, outpatient solution that can be performed in a variety of healthcare settings from hospitals and ambulatory surgical centers to clinics in emerging markets.
The device meets the FDA's stringent Breakthrough criteria:
Providing a unique, novel and more effective treatment for patients with contained disc herniations.
Representing a true technological innovation in the spinal care landscape.
Demonstrating significant advantages in terms of safety, recovery time, cost, and accessibility.
Showing strong potential to improve outcomes across diverse economic and geographic contexts, including under-resourced health systems.
Meeting an Urgent Global Need
Lumbar disc herniation affects millions of people globally and is a leading contributor to chronic pain, loss of mobility, reduced productivity, and diminished quality of life. Existing treatments often fall into two extremes: conservative care, which may not always bring relief, or invasive surgery, which carries risks, high costs, and extended recovery times.
Triojection fills a critical therapeutic gap. It offers an evidence-based, low-barrier, cost-effective alternative that can be deployed rapidly and with minimal infrastructure ideal for both advanced and developing market health systems.
"Our mission is to transform spine care and make meaningful minimalist solutions accessible to all," said Prof. Kieran Murphy MD, Chairman, Founder and Chief Medical Officer at SpinaFX. "This designation by the FDA validates the scientific merit of Triojection and 21 years of work by many people who have helped get us to this point. It's a vote of confidence in the future of inventiveness in spine health. We sincerely thank all our investors for their support and trust."
Backed by Global Expertise and Scientific Rigor
This regulatory milestone is the result of over two decades of research and development, including multiple international studies and collaborations with leading clinical experts in Italy, Switzerland, Greece, the United States and Canada. SpinaFX acknowledges the contributions of its diverse network of engineers and investigators, including Prof. Mario Muto (Italy) and Prof. Alexis Kelekis (Greece), both pioneers in the field of Interventional Neuroradiology.
Clinical data supporting Triojection's efficacy continues to build, with upcoming publications expected to highlight its outcomes across multicenter trials. The company's engineering, regulatory, and clinical affairs teams along with trusted partners across Europe and the United States have played a critical role in advancing the technology toward approval and adoption.
A Platform for Future Innovation
Beyond this first indication, SpinaFX is exploring additional applications of its oxygen-ozone delivery platform in treating other disc-related conditions and musculoskeletal disorders. The company is also expanding its educational programs to train physicians in safe, effective, and evidence-based use of the Triojection procedure.
"Our team is honored to receive this designation, but we view it as just the beginning," said Jeff Cambra, CEO of SpinaFX. "We're committed to working hand-in-hand with the FDA to bring Triojection to patients in the U.S. and beyond. Our goal is to create a new standard in spine care that's efficient, scalable, and deeply patient-centered. "
About SpinaFX
SpinaFX Medical Inc. is a Canadian-based medical technology company specializing in minimally invasive, image-guided therapies for spinal disorders. Its proprietary technology platform offers non-surgical solutions for treating disc-related conditions, using a unique approach to oxygen-ozone therapy. Committed to democratizing access to advanced spine care, SpinaFX collaborates with leading academic institutions, clinicians, and healthcare providers across the globe.
Forward-Looking Statement
This news release contains predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance, referred to herein as "forward-looking statements", which are made as of the date of this news release or as of the effective date of information described in this release, as applicable. The forward-looking statements address anticipated events or occurrences which may include economic factors, industry trends, market demand, and corporate performance and profitability, that may have an impact on SpinaFX's success. Forward-looking statements are often identified through words or expressions including "expects", "anticipates", "plans", "projects", "estimates", "envisages", "assumes", "intends", "strategy", "goals", "objectives" or variations thereof or stating that certain actions, events or results "may", "can", "could", "would", "might" or "will" be taken, occur or be achieved, or the negative of any of these terms and similar expressions.
All forward-looking statements are based on current beliefs as well as various assumptions made by, and information currently available to SpinaFX's management team. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that estimates, forecasts, projections, and other forward-looking statements will not be achieved or that assumptions do not reflect future experience. We caution any person reviewing this news release not to place undue reliance on these forward-looking statements as several important factors could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, anticipations, estimates, assumptions and intentions expressed in such forward-looking statements. Neither SpinaFX nor its representatives undertake to update any forward-looking statement, whether written or oral, that may be made from time to time by SpinaFX or its representatives or on behalf of either of them, except as may be required by law.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Canada News.Net
10 hours ago
- Canada News.Net
Costco to remove mifepristone from shelves at all U.S. pharmacies
ISSAQUAH, Washington: Costco Wholesale will end sales of the abortion pill mifepristone at all of its more than 500 U.S. pharmacy locations, citing limited demand from customers and patients. In a statement, the retailer said its decision "has not changed" and was based on the observation that most patients obtain the drug directly from their healthcare providers. The move comes as anti-abortion activist groups, including Inspire Investing and Alliance Defending Freedom, have campaigned to pressure major retailers to stop carrying the medication. Similar campaigns targeted Costco, Kroger, Walmart, and Albertsons last year. They are now shifting focus to Walgreens and CVS Health, which continue dispensing the pill in states where it remains legal. "Many retailers have become more cautious about taking overt political or social stances after recent controversies triggered boycotts, negative media coverage, and polarized consumer reactions," said Arun Sundaram, senior analyst at CFRA. Walgreens notes on its website that the U.S. Supreme Court's ruling on mifepristone access allows it to continue dispensing the drug under FDA guidelines. Kroger said it is reviewing the FDA's updated Risk Evaluation and Mitigation Strategy for the medication, while CVS told Reuters it fills mifepristone prescriptions in select states where it is legally permitted. Walmart declined to comment. Mifepristone, approved by the FDA in 2000 for use with misoprostol, ends early pregnancies of up to 10 weeks. The drug works by blocking progesterone, a hormone that supports the uterine lining during pregnancy; misoprostol is taken afterward to complete the process.
Globe and Mail
a day ago
- Globe and Mail
Novo Nordisk's Wegovy gets accelerated U.S. approval for liver disease
Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug Wegovy to treat a serious liver condition known as metabolic dysfunction-associated steatohepatitis. The decision makes Wegovy the first GLP-1 class therapy cleared for MASH, a progressive liver condition that affects around 5% of adults in the U.S., according to the American Liver Foundation. The approval is for use alongside a reduced-calorie diet and increased physical activity. The FDA's approval was based on part one of a two-part study that showed Wegovy helped more patients with MASH and liver scarring improve the organ's condition, compared to a placebo. At 72 weeks, nearly 37% of patients on Wegovy saw an improvement in liver fibrosis, compared to 22.4% on placebo. Nearly 63% of those on Wegovy had their liver inflammation resolved, versus 34.3% for placebo. No worsening of the disease was seen in these patients. Accelerated approvals allow the agency to move therapies that target serious and life-threatening conditions to the market more quickly. However, such approvals have been criticized because some drugs have later been proven to be ineffective.
Cision Canada
2 days ago
- Cision Canada
LG LAUNCHES THE OPTIMISM METER TO HELP CANADIANS SPREAD POSITIVITY THROUGH MUSIC Français
LG invites Canadians to spread the Life's Good message by creating and sharing songs that bring optimism to others TORONTO, Aug. 15, 2025 /CNW/ - LG Electronics Canada, Inc. (LG Canada) wants to strike a chord with Canadians with the launch of the Optimism Meter – a new initiative designed to amplify and track the power of optimism. LG believes that choosing optimism makes Life Good and the Optimism Meter underscores this belief. Research shows a strong connection between music and positive emotions with more than 60% of participants in a recent survey identifying music as their most frequently used non-pharmacological cognitive enhancer. 1 With this, LG invites Canadians to contribute to the Optimism Meter, and move the meter, by creating a personalized song, and sharing it with someone special using its new AI music tool, Radio Optimism. Every track shared with #OptimismWins, #LifesGood, and #RadioOptimism fuels the Optimism Meter and helps unlock a $25,000 donation to benefit the MLSE Foundation. "Music isn't just background sound – it's one of the most powerful emotional tools we have. Whether we're trying to shake off a bad mood, calm our nerves, or tap into joy, people instinctively turn to music to regulate how they feel," commented Dr. Frank A. Russo, Cognitive Neuroscientist and Director of the Science of Music, Auditory Research and Technology (SMART) Lab. "It helps us understand our emotions and express what words can't. But perhaps just as important, music connects us to others. Singing or listening together can synchronize heart rates and even brain activity, fostering empathy and trust. Research has shown that music can reduce stress hormones like cortisol, boost bonding hormones like oxytocin, and make us feel closer – especially when we share a musical experience with others. At a neurological level, music activates the same reward circuits in the brain as food, and social connection. This might explain why surveys have consistently found that music is one of the most common non-prescription strategies for managing mood. Music helps us feel better, together." A global study from LG reveals similar findings. In fact, one-third of Canadians polled believe sharing feelings through emotional content [such as music] and media is one of the most necessary ways to build meaningful connections and ultimately fuel optimism. 2 This belief is supported by the understanding that having shared musical experiences, even when asynchronous, can allow people to appreciate their common humanity. 3 Furthermore, the act of engaging with music together can release oxytocin, promoting social bonding. 4 Radio Optimism transforms this concept into an interactive platform where participants can create and send personalized songs to their loved ones. Users can easily create new songs using AI-powered tools, which are thoroughly trained on a curated music dataset. These tools interpret user prompts to produce unique musical pieces and generate matching album art, providing an engaging and personalized experience. Once generated, these songs can be sent to recipients to deepen their connection and be shared online for others to discover worldwide. Canadians can participate in the Optimism Meter by: Sharing how music fuels their optimism on social media using #OptimismWins #LifesGood #RadioOptimism Creating and sharing personalized songs with Radio Optimism using #RadioOptimism #LifesGood #OptimismWins Visiting to learn more about the campaign and track the progress of the Optimism Meter. Every comment, post, and song shared with the campaign hashtags will contribute to the Optimism Meter, and unlock various milestones, culminating in a $25,000 donation to the MLSE Foundation. Focused on helping youth reach their full potential through sport, MLSE Foundation helps young people facing barriers thrive by providing free access to programs that support physical health, mental well-being, education, and career readiness. One standout program is the dance program at MLSE LaunchPad that empowers young girls through movement and music. With mentorship from North Side Crew, the Toronto Raptors dance team, and a recent showcase win, the program continues to inspire confidence, creativity, and connection. The Optimism Meter is more than just a campaign; it's an invitation to celebrate the joy of music, connect with others, and make a positive impact on communities across Canada. Together, let's spread the good vibes and show that Life's Good when #OptimismWins! Learn more and join the movement at About LG Electronics Canada, Inc. LG Electronics Canada, Inc. is the Canadian subsidiary of LG Electronics Inc., a global sales innovator in technology and manufacturing headquartered in Seoul, South Korea. LG Electronics Canada, with its head office in Toronto, Ontario, is comprised of three business units - Home Appliances Solution, Media Entertainment Solution, and Eco Solution. LG Electronics Canada is focused on delivering award-winning products known for blending style and technology. These innovative products include TVs, audio solutions and portable devices, home appliances, residential and commercial air solutions, computer monitors and laptops, and industry-leading OLED and LED digital display solutions. For more information, visit
